News

BiPar has initiated the pivotal phase 3 trial for BSI-201 in combination with chemotherapy. The trial is on patients with metastatic triple-negative breast cancer (mTNBC), defined by tumors

With immediate effect, Bayer MaterialScience has lifted force majeure for the polyurethane raw material toluene diisocyanate (TDI) in Europe, the Middle East, Africa (EMEA) region. The damage to

Adeona has provided results of a 90 subject prospective, blinded, observational clinical study to evaluate copper and zinc status in Alzheimer’s disease, Parkinson’s disease and normal subjects. The

American Medical (AMS), a provider of medical solutions for restoring men’s and women’s pelvic health, has announced that its AMS 700 with INHIBIZONE has been approved by the

Sanofi-Aventis has released a report by a multidisciplinary board of renowned international experts, following an in-depth assessment of the recent publications of registry analyses with Lantus in Diabetologia.

Velos has released a software to support cancer centers with new workflow and content for the US National Cancer Institute (NCI) Clinical Trials Reporting Program (CTRP). The company

Champions Biotechnology has collaborated with Do-Coop for development of a more soluble form of SG410, its Benzoylphenylurea (BPU) sulfur analog compound. Do-Coop has said that using Neowater, a

BioDelivery (BDSI) and Meda have received FDA approval to market Onsolis (fentanyl buccal soluble film), formerly referred to as Bema Fentanyl. It is for the management of breakthrough

Latitude (LPI) has initiated two new collaboration studies for its Phospholipid Gel (PG) Depot drug delivery platform. The company said that the new studies bring the total to